Michael T. Zimmermann

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Raul A. Urrutia · 5 shared papers, 2021–2026 · strength 1.15
   • Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
   • Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
   • Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
2. Gwen Alyce Lomberk · 5 shared papers, 2021–2026 · strength 1.15
   • Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
   • Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
   • Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
3. Gareth Pollin · 3 shared papers, 2024–2026 · strength 0.87
   • Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
   • Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
   • Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
4. Juan Iovanna · 2 shared papers, 2023–2026 · strength 0.46
   • Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
   • Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
5. Madeline M. Dzikowski · 1 shared paper, 2026 · strength 0.29
   • Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
6. Analía Meilerman Abuelafia · 1 shared paper, 2023 · strength 0.16
   • Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
7. Rémy Nicolle · 1 shared paper, 2023 · strength 0.16
   • Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
8. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2023 · strength 0.16
   • Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
9. Nelson Dusetti · 1 shared paper, 2023 · strength 0.16
   • Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
10. Mohammed Aldakkak · 1 shared paper, 2021 · strength 0.12
    • Paper Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene… DOI 10.3389/fonc.2021.606820↗
11. Douglas B. Evans · 1 shared paper, 2021 · strength 0.12
    • Paper Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene… DOI 10.3389/fonc.2021.606820↗
12. Susan Tsai · 1 shared paper, 2021 · strength 0.12
    • Paper Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene… DOI 10.3389/fonc.2021.606820↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.